Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Zydus Lifesciences Ltd. Share Price
Day's Range
Day's Range
Low
₹1,036.80
High
₹1,047.45
Price Summary
| Previous Close | ₹1,042.95 |
|---|---|
| Day's Range | ₹1,036.80 - ₹1,047.45 |
| Open | ₹1,041.00 |
| 52 Week Range | ₹835.50 - ₹1,093.65 |
| Volume | 5,98,285 |
| Market Cap | ₹0.10 |
| Previous Close | ₹1,042.00 |
|---|---|
| Day's Range | ₹1,038.00 - ₹1,047.50 |
| Open | ₹1,042.80 |
| 52 Week Range | ₹835.85 - ₹1,093.95 |
| Volume | 15,860 |
| Market Cap | ₹0.10 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 6,239.81 |
|---|---|
| Market Cap (₹ in Mn) | 0.10 |
| Dividend Yield(%) | 0.10 |
| Price/Earning (TTM) | 20.69 |
| TTM EPS (₹) | 50.09 |
| P/E Ratio | 19.69 |
| Book Value(₹) | 3.85 |
| PAT Margin (%) | 10.10 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 26.06 |
| Trade Value ( ₹ in Lacs) | 165.26 |
|---|---|
| Market Cap (₹ in Mn) | 0.10 |
| Dividend Yield(%) | 0.10 |
| Price/Earning (TTM) | 20.69 |
| TTM EPS (₹) | 50.09 |
| P/E Ratio | 19.69 |
| Book Value(₹) | 3.85 |
| PAT Margin (%) | 10.10 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 26.06 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 65279.0 | 151163.0 |
| Expenses | N/A | N/A |
| PBT | 16669.0 | 74447.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 12437.0 | 57749.0 |
About Zydus Lifesciences Ltd.
| Founded | 1995 |
|---|---|
| Managing Director | Sharvil P Patel |
| NSE Symbol | ZYDUSLIFE |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,53,750.23 | 1,865.95 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,82,116.76 | 6,837.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,51,313.88 | 4,528.70 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,19,400.22 | 8,395.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,13,225.36 | 1,398.70 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,10,037.00 | 1,310.00 | 1,148.40 - 1,148.40 |
| Max Healthcare Institute Ltd. | 1,06,234.43 | 1,050.00 | 903.00 - 903.00 |
| Lupin Ltd. | 1,04,489.83 | 2,280.40 | 1,836.80 - 1,836.80 |
| Zydus Lifesciences Ltd. | 1,04,265.97 | 1,042.00 | 835.50 - 835.50 |
| Mankind Pharma Ltd. | 1,03,844.60 | 2,500.00 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Zydus Lifesciences informs about outcome of board meeting
Zydus Lifesciences has informed that the Board of Directors at their meeting held today, May 19, 2026, has approved: 1. holding of Thirty First Annual General Meeting (‘AGM’) of the members of the Company on Tuesday, August 11, 2026, through Video Conference / Other Audio Visual Means, 2. final dividend of Re 1 (@ 100%) per equity share of Re 1 each, subject to approval of the shareholders at the AGM and 3. the Record Date as Friday, July 24, 2026, in compliance with regulation 42(1) of the Listing Regulations, to determine the list of shareholders entitled to receive the final dividend for the Financial Year ended on March 31, 2026, payment of which shall be subject to the approval by the members at the AGM. The Company shall make the payment of dividend, subject to deduction of tax at source, on or around Friday, August 14, 2026, subject to the approval of the same by the shareholders at the AGM.
Zydus Lifesciences informs about investor presentation
Zydus Lifesciences informs about update on board meeting
Zydus Lifesciences informs about change in director
Pursuant to the provisions of regulation 30 read with clause 7 of para A of part A of Schedule III of the Listing Regulations, Zydus Lifesciences has informed that S. Diwanji (DIN: 00032072) ceased as the Director (including as the Independent Director) effective Tuesday, May 12, 2026, consequent upon completion of his tenure. The Company places on record its sincere appreciation for the valuable contributions made by Diwanji during his tenure. The Company also expressed its gratitude for Diwanji’s dedication, integrity, and professional expertise, which have enriched deliberations and decision-making processes. The requisite details as per the SEBI Master Circular are attached as Annexure – ‘A’.
The above information is a part of company’s filings submitted to BSE.
Zydus Lifesciences informs about press release
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Zydus Lifesciences Ltd. is ₹1,042.95 as of 2026-05-22.
The market capitalisation of Zydus Lifesciences Ltd. is ₹104,265.97 as of 2026-05-21.
The 1-year return of Zydus Lifesciences Ltd. is 6.50% as of 2026-05-22.
The P/E ratio of Zydus Lifesciences Ltd. is 19.69 as of 2026-05-22.
The 52-week high and low of Zydus Lifesciences Ltd. are ₹1,093.65 and ₹835.50, respectively, as of 2026-05-22.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
